

Supplementary Data

Indole- and Pyrazole-Glycyrrhetic Acid Derivatives as PTP1B Inhibitors: Synthesis, In Vitro and In Silico Studies

Ledy De-la-Cruz-Martínez ^{1,2,†}, Constanza Duran-Becerra ^{1,†}, Martín González-Andrade ³, José C. Páez-Franco ⁴, Juan Manuel Germán-Acacio ⁴, Julio Espinosa-Chávez ⁵, J. Martín Torres-Valencia ⁶, Jaime Pérez-Villanueva ¹, Juan Francisco Palacios-Espinosa ¹, Olivia Soria-Arteche ¹ and Francisco Cortés-Benítez ^{1,*}

¹ Departamento de Sistemas Biológicos, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Xochimilco (UAM-X), 04960 Ciudad de México, Mexico; 2193800101@alumnos.xoc.uam.mx (L.D.-I.-C.-M.); 2163025430@alumnos.xoc.uam.mx (C.D.-B.); jpvillanueva@correo.xoc.uam.mx (J.P.-V.); jpalacios@correo.xoc.uam.mx (J.F.P.-E.); soriao@correo.xoc.uam.mx (O.S.-A.)

² Maestría en Ciencias Farmacéuticas, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Xochimilco (UAM-X), 04960 Ciudad de México, Mexico

³ Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 Ciudad de México, Mexico; martin@bq.unam.mx

⁴ Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 14000 Ciudad de México, Mexico; paez@cic.unam.mx (J.C.P.-F.); jmga@cic.unam.mx (J.M.G.-A.)

⁵ Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, 58030 Michoacán, Mexico; julioespinoza30@hotmail.com

⁶ Área Académica de Química, Universidad Autónoma del Estado de Hidalgo, 42184 Hidalgo, Mexico; jmartin@uaeh.edu.mx

† These authors contributed equally to this work.

* Correspondence: jcortesb@correo.xoc.uam.mx; Tel.: +52-55-5483-4000 (ext. 7259)

Table with ¹H and ¹³C NMR chemical shifts (δ) of compounds **4f** and **5f**. ¹H NMR and ¹³C NMR spectra of final compounds. Spectra resulting from different NMR experiments (NOESY, COSY, HSQC and HMBC) of compounds **4f** and **5f**. UPLC-ESI-MS data of final compounds are available.

Table S1. ^1H and ^{13}C NMR chemical shifts (δ) of compounds **4f** and **5f**

H/C number ^a V	^1H NMR δ (ppm) ^a	^{13}C NMR δ (ppm) ^a	H/C number ^b	^1H NMR δ (ppm) ^b	^{13}C NMR δ (ppm) ^b	
1	a l	2.3 and 4.0 -	37.5 108.4	1 2	2.17 and 3.55 -	37.03 114.40
3	e	-	142.07	3	-	145.79
4	s	-	34.2	4	-	34.45
5		1.44	53.1	5	1.32	53.58
6	d	1.39 and 1.72	18.68	6	1.52 and 1.68	18.05
7	e	1.55 and 1.80	32.2	7	1.42 and 1.70	31.80
8	t	-	45.5	8	-	44.71
9	e	-	60.5	9	2.57	59.76
10	m	-	38.1	10	-	37.75
11	i	-	199.8	11	-	198.85
12	n	5.80	129.01	12	5.47	127.46
13	e	-	169.30	13	-	170.36
14	d	-	44.01	14	-	44.84
15	f	1.28 and 2.08	27.74	15	1.35 and 1.80	26.40
16	o	1.07 and 2.06	26.63	16	0.99 and 2.10	26.04
17	r	-	31.10	17	-	31.46
18		-	48.3	18	2.06	48.25
19	c	1.69 and 2.02	41.10	19	1.69 and 2.11	41.02
20	o	-	43.5	20	-	43.31
21	m	1.55 and 1.79	32.06	21	1.33 and 1.83	30.59
22	p	1.37 and 1.44	37.92	22	1.25 and 1.36	37.70
23	u	1.27	23.51	23	0.97	29.54
24	n	1.33	31.14	24	0.94	22.74
25	d	1.18	16.16	25	1.04	15.63
26	4	1.24	28.73	26	1.08	18.12
27	f	1.23	18.50	27	1.08	28.03
28	b	0.87	28.57	28	0.75	28.18
29		1.42	23.59	29	1.35	23.07
30	V	-	182.06	30	-	177.76
3a'	a	-	137.75	1'	-	145.95
4'	l	7.79	116.39	2'	7.86	126.12
5'	u	-	121.58	3'	7.61	130.19
6'	e	7.34	118.00	4'	7.86	126.15
7'	s	7.34	110.38	5'	7.61	129.74
7a'	d	-	127.86	6'	-	126.08
CF ₃	e	-	126.10	CF ₃	-	122.75
NH	t	7.91	-	Pyrazole-CH	7.36	138.69

determined for compound **5f**




Figure S1. ^1H NMR (600 MHz) spectrum of compound **4a** in CDCl_3




Figure S2. ^{13}C NMR (151 MHz) spectrum of compound **4a** in CDCl_3




Figure S3. ^1H NMR (600 MHz) spectrum of compound **4b** in CDCl_3




Figure S4. ^{13}C NMR (151 MHz) spectrum of compound **4b** in CDCl_3




Figure S5. ^1H NMR (600 MHz) spectrum of compound **4c** in CDCl_3




Figure S6. ^{13}C NMR (151 MHz) spectrum of compound **4c** in CDCl_3




Figure S7. ^1H NMR (600 MHz) spectrum of compound **4d** in CDCl_3




Figure S8. ^{13}C NMR (151 MHz) spectrum of compound **4d** in CDCl_3




Figure S9. ^1H NMR (600 MHz) spectrum of compound **4e** in CDCl_3




Figure S10. ^{13}C NMR (151 MHz) spectrum of compound **4e** in CDCl_3




Figure S11. ^1H NMR (400 MHz) spectrum of compound **4f** in CDCl_3




Figure S12. ^{13}C NMR (151 MHz) spectrum of compound **4f** in CDCl_3




Figure S13. HSQC spectrum of compound **4f** in CDCl_3




Figure S14. HSQC spectrum (0 – 3.0 ppm) of compound **4f** in CDCl_3




Figure S15. HMBC spectrum of compound **4f** in CDCl_3




Figure S16. HMBC spectrum (0 – 3.0 ppm) of compound **4f** in CDCl_3




Figure S17. COSY spectrum of compound **4f** in CDCl_3




Figure S18. COSY spectrum (0 – 3.0 ppm) of compound **4f** in CDCl_3




Figure S19. NOESY spectrum of compound **4f** in CDCl_3




Figure S20. NOESY spectrum (0 – 3.0 ppm) of compound **4f** in CDCl_3




Figure S21. ^1H NMR (600 MHz) spectrum of compound **5a** in CDCl_3




Figure S22. ^{13}C NMR (151 MHz) spectrum of compound **5a** in CDCl_3




Figure S23. ^1H NMR (400 MHz) spectrum of compound **5b** in CDCl_3




Figure S24. ^{13}C NMR (151 MHz) spectrum of compound **5b** in CDCl_3




Figure S25. ^1H NMR (400 MHz) spectrum of compound **5c** in CDCl_3




Figure S26. ^{13}C NMR (151 MHz) spectrum of compound **5c** in CDCl_3




Figure S27. ^1H NMR (400 MHz) spectrum of compound **5d** in CDCl_3




Figure S28. ^{13}C NMR (151 MHz) spectrum of compound **5d** in CDCl_3




Figure S29. ^1H NMR (400 MHz) spectrum of compound **5f** in CDCl_3




Figure S30. ^{13}C NMR (151 MHz) spectrum of compound **5f** in CDCl_3




Figure S31. ^1H NMR (400 MHz) spectrum of compound **5f** in DMSO-d_6




Figure S32. ^{13}C NMR (151 MHz) spectrum of compound **5f** in DMSO-d_6




Figure S33. HSQC spectrum of compound **5f** in DMSO-d_6




Figure S34. HSQC spectrum (0 – 2.7 ppm) of compound **5f** in DMSO-d₆




Figure S35. HMBC spectrum of compound **5f** in DMSO-d_6




Figure S36. HMBC spectrum (0 – 2.8 ppm) of compound **5f** in DMSO-d₆




Figure S37. COSY spectrum of compound 5f in DMSO-d₆




Figure S38. COSY spectrum (0 – 3.0 ppm) of compound **5f** in DMSO-d₆




Figure S39. NOESY spectrum of compound 5f in DMSO-d₆





Figure S40. NOESY spectrum (0 – 3.0 ppm) of compound **5f** in DMSO-d₆

For the synthesis of indole-GA series, it is important to mention that we did not use *meta*-phenylhydrazines because we will obtain isomeric mixtures of these compounds which are difficult to purify.

SAMPLE INFORMATION


Sample Name: FC-1-47
Sample Type: Unknown
Vial: 2:A,2
Injection #: 1
Run Time: 7.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 17 FC 1 47 dil
Acq. Method Set: ID 001 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/2/2021 11:41:27 AM CDT



Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	FC-1-47	4.786	119035283	11807244	QDa 1: MS Scan




UPLC-ESI-MS data of compound 4a

FC-1-47 - 4.786 - QDa 1: MS Scan

542.3

543.3

Apex




UPLC–ESI–MS data of compound 4a

SAMPLE INFORMATION


Sample Name: CDB-2-24
Sample Type: Unknown
Vial: 2:B,3
Injection #: 1
Run Time: 7.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 2 CDB 2 24 Dil
Acq. Method Set: ID 002 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/2/2021 2:33:20 PM CDT





Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	CDB-2-24	4.585	65457670	8703762	QDa 1: MS Scan



UPLC-ESI-MS data of compound 4b

CDB-2-24 - 4.585 - QDa 1: MS Scan




UPLC–ESI–MS data of compound 4b

SAMPLE INFORMATION


Sample Name: FC-1-113
Sample Type: Unknown
Vial: 2:C,2
Injection #: 1
Run Time: 7.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 2 FC 1 113 Dil
Acq. Method Set: ID 004 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/4/2021 10:03:55 AM CDT





Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	FC-1-113	5.118	100670643	11069832	QDa 1: MS Scan



UPLC–ESI–MS data of compound 4c

FC-1-113 - 5.118 - QDa 1: MS Scan




UPLC–ESI–MS data of compound 4c

SAMPLE INFORMATION


Sample Name: FC-1-121
Sample Type: Unknown
Vial: 2:E,2
Injection #: 1
Run Time: 8.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 2 FC 1 121
Acq. Method Set: ID 006 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/4/2021 11:03:52 AM CDT







Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	FC-1-121	6.235	132861055	12900302	QDa 1: MS Scan



UPLC-ESI-MS data of compound 4d

FC-1-121 - 6.235 - QDa 1: MS Scan




UPLC-ESI-MS data of compound 4d

SAMPLE INFORMATION


Sample Name: FC-1-109
Sample Type: Unknown
Vial: 2:D,2
Injection #: 1
Run Time: 8.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 2 FC 1 109 Dil
Acq. Method Set: ID 005 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/4/2021 10:32:00 AM CDT







Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	FC-1-109	6.510	57968220	5089974	QDa 1: MS Scan



UPLC–ESI–MS data of compound 4e

FC-1-109 - 6.510 - QDa 1: MS Scan




UPLC–ESI–MS data of compound 4e

SAMPLE INFORMATION


Sample Name: FC-1-114
Sample Type: Unknown
Vial: 2:F,2
Injection #: 1
Run Time: 8.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 2 FC 1 114 Dil
Acq. Method Set: ID 007 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/4/2021 11:34:13 AM CDT





Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	FC-1-114	7.001	64379463	5143460	QDa 1: MS Scan



UPLC-ESI-MS data of compound 4f

FC-1-114 - 7.001 - QDa 1: MS Scan




UPLC–ESI–MS data of compound 4f

SAMPLE INFORMATION


Sample Name: DLC-3-8
Sample Type: Unknown
Vial: 2:A,3
Injection #: 1
Run Time: 8.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 2 DLC 3 8
Acq. Method Set: ID 008 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/4/2021 12:26:06 PM CDT







Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	DLC-3-8	6.355	175052351	18027727	QDa 1: MS Scan



UPLC-ESI-MS data of compound 5a

DLC-3-8 - 6.355 - QDa 1: MS Scan




UPLC–ESI–MS data of compound 5b

SAMPLE INFORMATION


Sample Name: FC-1-122
Sample Type: Unknown
Vial: 2:B,3
Injection #: 1
Run Time: 10.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 2 FC 1 122
Acq. Method Set: ID 013 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/21/2021 1:19:33 PM CDT







Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	FC-1-122	8.721	163186315	12882045	QDa 1: MS Scan



UPLC–ESI–MS data of compound 5c

FC-1-122 - 8.721 - QDa 1: MS Scan




UPLC–ESI–MS data of compound 5c

SAMPLE INFORMATION


Sample Name: FC-1-115
Sample Type: Unknown
Vial: 2:B,2
Injection #: 1
Run Time: 10.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 2 FC 1 115
Acq. Method Set: ID 011 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/21/2021 1:08:41 PM CDT





Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	FC-1-115	6.238	84701456	8589486	QDa 1: MS Scan



UPLC–ESI–MS data of compound 5d

FC-1-115 - 6.238 - QDa 1: MS Scan




UPLC–ESI–MS data of compound 5d

SAMPLE INFORMATION


Sample Name: FC-1-119
Sample Type: Unknown
Vial: 2:A,4
Injection #: 1
Run Time: 11.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 1 FC 1 119
Acq. Method Set: ID 012 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/21/2021 12:37:11 PM CDT







Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	FC-1-119	9.472	256951373	19564042	QDa 1: MS Scan



UPLC–ESI–MS data of compound 5e

FC-1-119 - 9.472 - QDa 1: MS Scan




UPLC–ESI–MS data of compound 5e

SAMPLE INFORMATION


Sample Name: FC-1-116
Sample Type: Unknown
Vial: 2:A,6
Injection #: 1
Run Time: 10.0 Minutes
Column Name:
ACQUITY UPLC HSS T3 1.8um 3.0 x 100 mm

Acquired By:
Sample Set Name 001 Prueba 1 FC 1 116
Acq. Method Set: ID 014 QPDA
Injection Volume: 10.00 ul
Date Acquired: 6/21/2021 12:49:01 PM CDT







Peak Results

	Name	RT	Area	Height	MS 3D Channel Name
1	FC-1-116	8.737	264967548	19878952	QDa 1: MS Scan



UPLC–ESI–MS data of compound 5f

FC-1-116 - 8.737 - QDa 1: MS Scan



UPLC–ESI–MS data of compound 5f